Status:
COMPLETED
Selenium Treatment in Autoimmune Thyroiditis (AIT)
Lead Sponsor:
Ege University
Conditions:
Autoimmune Thyroiditis
Hashimotos Thyroiditis
Eligibility:
FEMALE
15-70 years
Phase:
NA
Brief Summary
Selenium suppresses autoimmune destruction of thyrocytes and decreases titers of serum TPOAb in AIT patients. Older 4 clinical trials approved the efficacy of the daily dose of 200micg. It's believed ...
Eligibility Criteria
Inclusion
- Clinically approved AIT patients who do not use any medication other than LT4 to keep TSH in the lower half of normal range.
Exclusion
- Any kind of drug use other than LT4 or any kind of known pathology which may effect GIS absorption.
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
August 1 2005
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00271427
Start Date
December 1 2004
End Date
August 1 2005
Last Update
August 23 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dep. of Nuc. Med., Ege University Faculty of Medicine.
Izmir, Turkey (Türkiye), 35100